| Trump tariff 'tornado' still hunting markets: Former Medtronic CEO |
You can catch Opening Bid on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. There has been one common theme from Corporate America throughout the last two months as the Trump administration's trade war has taken hold: shot-calling CEOs have been frozen in their normally hard-charging tracks. |
youtube.com |
2025-05-16 14:38:16 |
Czytaj oryginał (ang.) |
| What Analyst Projections for Key Metrics Reveal About Medtronic (MDT) Q4 Earnings |
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended April 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-05-16 14:21:11 |
Czytaj oryginał (ang.) |
| Should You Continue to Hold Medtronic Stock in Your Portfolio Now? |
Investors stay optimistic about MDT due to its strength in the Cardiovascular portfolio. |
zacks.com |
2025-05-16 12:51:07 |
Czytaj oryginał (ang.) |
| Medtronic (MDT) Stock Declines While Market Improves: Some Information for Investors |
Medtronic (MDT) closed the most recent trading day at $84.25, moving -1.01% from the previous trading session. |
zacks.com |
2025-05-14 22:50:40 |
Czytaj oryginał (ang.) |
| Medtronic: Quite A Few Supportive Sub-Plots Ahead Of The Q4-25 Earnings |
Medtronic has outperformed the S&P500 and other healthcare stocks from the S&P500 this year, but now faces a pivotal earnings event on the 21st of May. Cardiovascular portfolio strength, especially from Pulse Field Ablation products, and a convalescing medical surgical outlook, underpin our optimism, while gross margin and SG&A progress is likely to be seen. While the expected dividend hike may not be meaningful (potentially at less than 2%), that's not because MDT doesn't have the capabilities to be more generous with strong FCF coverage. |
seekingalpha.com |
2025-05-14 13:54:16 |
Czytaj oryginał (ang.) |
| Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing |
In the closing of the recent trading day, Medtronic (MDT) stood at $83.62, denoting a +0.55% change from the preceding trading day. |
zacks.com |
2025-05-08 22:45:31 |
Czytaj oryginał (ang.) |
| Is Medtronic Stock a Buy Pre-Q4 Earnings? Key Metrics to Watch |
Despite challenges, Medtronic demonstrates the resilience of its underlying business fundamentals, delivering consistent mid-single-digit organic revenue growth. |
zacks.com |
2025-05-08 20:00:46 |
Czytaj oryginał (ang.) |
| Medtronic to announce financial results for its fourth quarter and full fiscal year 2025 |
GALWAY, Ireland , May 7, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025. A news release will be issued at approximately 5:45 a.m. |
prnewswire.com |
2025-05-07 22:07:00 |
Czytaj oryginał (ang.) |
| New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women |
Star Jones, award winning television personality & women's heart health advocate, helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign GALWAY, Ireland , May 7, 2025 /PRNewswire/ -- A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S., many women are still unaware of the risk and the importance of heart health. |
prnewswire.com |
2025-05-07 14:02:00 |
Czytaj oryginał (ang.) |
| This Magnificent High-Yield Dividend Stock Just Became an Even Better Buy |
Medical device specialist Medtronic (MDT 1.38%) has not performed well over the past five years; the stock has significantly lagged broader equities. One of the issues it's encountered is slow revenue growth. |
fool.com |
2025-05-03 13:45:00 |
Czytaj oryginał (ang.) |
| Medtronic (MDT) Surpasses Market Returns: Some Facts Worth Knowing |
Medtronic (MDT) closed the most recent trading day at $84.85, moving +1.54% from the previous trading session. |
zacks.com |
2025-05-02 22:50:39 |
Czytaj oryginał (ang.) |
| Medtronic (MDT) Rises Higher Than Market: Key Facts |
Medtronic (MDT) concluded the recent trading session at $84.76, signifying a +0.19% move from its prior day's close. |
zacks.com |
2025-04-30 22:55:45 |
Czytaj oryginał (ang.) |
| Smart Pills Market Industry Trend Analysis, and Forecast 2025-2034, with Profiles of ANX Robotica, Bodycap, CapsoVision, Check-Cap, etectRx, Intromedic, Medtronic, Otsuka, Olympus and RF |
Key growth drivers include the rise of gastrointestinal disorders and demand for non-invasive diagnostics. Smart pills, equipped with sensors and AI, facilitate real-time monitoring and personalized medicine. North America leads with USD 455.5 million in 2024. The market benefits from tech advancements, an aging population, and robust healthcare infrastructure, paving the way for continuous growth. Key growth drivers include the rise of gastrointestinal disorders and demand for non-invasive diagnostics. Smart pills, equipped with sensors and AI, facilitate real-time monitoring and personalized medicine. North America leads with USD 455.5 million in 2024. The market benefits from tech advancements, an aging population, and robust healthcare infrastructure, paving the way for continuous growth. |
globenewswire.com |
2025-04-30 15:24:00 |
Czytaj oryginał (ang.) |
| Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients |
One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib Dual-energy (RF/PF), focal Sphere-9™ catheter demonstrates efficacy for linear ablation in persistent AFib Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meeting GALWAY, Ireland and SAN DIEGO , April 26, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera™ family of technologies, including the next-generation Sphere-360™ single-shot pulsed field ablation (PFA) catheter and the groundbreaking Sphere-9™ combination mapping and dual-energy focal PFA catheter. Data were presented in High Impact Science Sessions at the Heart Rhythm Society 2025 Annual Meeting in San Diego; the Sphere-360 study was simultaneously published in the Heart Rhythm Journal. |
prnewswire.com |
2025-04-26 23:20:00 |
Czytaj oryginał (ang.) |
| 2 Outstanding Dividend Stocks to Buy and Hold For 20 Years |
Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold on through market volatility. In fact, it's still a great time to invest in companies that have excellent underlying businesses and attractive long-term prospects. |
fool.com |
2025-04-26 18:32:00 |
Czytaj oryginał (ang.) |
| Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system |
Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as a late-breaker at the American Urologic Association annual meeting Company confirms Hugo RAS system submission to the U.S. Food and Drug Administration GALWAY, Ireland and LAS VEGAS , April 26, 2025 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced that the Expand URO Investigational Device Exemption (IDE) clinical study, the largest such study for robotic-assisted urologic surgery ever conducted, met both primary safety and effectiveness endpoints. The prospective, multi-center, single-arm IDE study included 137 patients who underwent urologic procedures using the Hugo™ robotic-assisted surgery (RAS) system. |
prnewswire.com |
2025-04-26 18:20:00 |
Czytaj oryginał (ang.) |
| 4 of Our Favorite Dividend Aristocrats Offer a Lifetime of Secure Passive Income |
Dividend stocks are a favorite among investors for good reason. They provide a steady income stream and offer a promising avenue for total return. |
247wallst.com |
2025-04-26 11:15:51 |
Czytaj oryginał (ang.) |
| Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results |
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: Late-breaking clinical study results evaluating the OmniaSecure lead for investigational use in the LBBAP location show high defibrillation success GALWAY, Ireland and SAN DIEGO , April 25, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure™ defibrillation lead for placement within the right ventricle. The lead, built on the highly reliable SelectSecure™ Model 3830 pacing lead and delivered via catheter, builds on the Medtronic portfolio of lead solutions designed for precise delivery and placement. |
prnewswire.com |
2025-04-25 21:45:00 |
Czytaj oryginał (ang.) |
| The Smartest Dividend Stocks to Buy With $2,000 Right Now |
Buying dividend stocks is always a smart plan. They have historically outperformed non-dividend payers by more than two-to-one (9.2% annualized return compared to 4.3% over the last 50 years, according to data from Hartford Funds and Ned Davis Research). |
fool.com |
2025-04-25 07:09:00 |
Czytaj oryginał (ang.) |
| Medtronic (MDT) Increases Yet Falls Behind Market: What Investors Need to Know |
Medtronic (MDT) reachead $84.30 at the closing of the latest trading day, reflecting a +0.66% change compared to its last close. |
zacks.com |
2025-04-24 22:50:56 |
Czytaj oryginał (ang.) |
| Medtronic explores options to optimize manufacturing operations amid Trump's tariff threats |
Medical device maker Medtronic is looking at options to modify its global manufacturing footprint as part of efforts to mitigate any impact of U.S. President Donald Trump's tariff plans, a company executive told Reuters on Tuesday. |
reuters.com |
2025-02-25 03:21:51 |
Czytaj oryginał (ang.) |
| Distributor Purchasing Shifts Mar MDT's Q3 Show: How to Play the Stock |
Medtronic's Medical Surgical segment faces challenges in the third quarter due to shifts in U.S. distributor buying patterns. |
zacks.com |
2025-02-24 15:15:21 |
Czytaj oryginał (ang.) |
| US FDA approves Medtronic's medical device for Parkinson's disease |
The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with Parkinson's disease, the medical device maker said on Monday. |
reuters.com |
2025-02-24 11:18:09 |
Czytaj oryginał (ang.) |
| Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's |
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland , Feb. 24, 2025 /PRNewswire/ -- For the one million people diagnosed with Parkinson's disease in the United States 1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug Administration (FDA) approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI). There is no cure for debilitating neurological conditions like Parkinson's, however, deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. |
prnewswire.com |
2025-02-24 11:00:00 |
Czytaj oryginał (ang.) |
| 2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream |
A higher dividend yield is nice because it allows you to collect more dividend income on every dollar you invest in a stock. However, the company paying that dividend needs to be healthy to ensure it can maintain its payout during the tough times that inevitably come. |
fool.com |
2025-02-24 09:30:00 |
Czytaj oryginał (ang.) |
| Is Medtronic Stock a Buy? |
Medical device manufacturer Medtronic (MDT 2.59%) is a healthcare industry stalwart. The company, based in the U.S. and Ireland, is one of the largest in its segment, developing and selling a diverse portfolio of products that includes hospital equipment and devices for cardiovascular care and diabetes. |
fool.com |
2025-02-21 13:21:00 |
Czytaj oryginał (ang.) |
| Medtronic's Expansion Gains Momentum—Time for a Market Shift? |
Medtronic's NYSE: MDT growth efforts and investments in medical technology innovation are starting to pay off. The company's pulsed field ablation (PFA) technology is a key growth driver, strengthening both its cardiac segment and overall business expansion. |
marketbeat.com |
2025-02-21 10:32:05 |
Czytaj oryginał (ang.) |
| The Smartest Dividend Stocks to Buy With $1,000 Right Now |
You have $1,000 (or $200 or $50,000) burning a hole in your pocket and you're itching to invest in some stocks. Might I suggest some dividend payers? |
fool.com |
2025-02-20 06:45:00 |
Czytaj oryginał (ang.) |
| Why Medtronic Stock Is Sinking Today |
Shares of Medtronic (MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. |
fool.com |
2025-02-18 15:08:08 |
Czytaj oryginał (ang.) |
| Empire State Manufacturing Increase More Than Expected |
Pre-market futures are starting a new holiday-shortened trading week higher, with all four major indexes currently riding in the green. The Dow is +81 points at this hour, the S&P 500 is +23, the Nasdaq +96 points and the small-cap Russell 2000 +9. |
zacks.com |
2025-02-18 13:51:14 |
Czytaj oryginał (ang.) |
| Medtronic plc (MDT) Q3 2025 Earnings Call Transcript |
Medtronic plc (NYSE:MDT ) Q3 2025 Earnings Conference Call February 18, 2025 8:00 AM ET Company Participants Ryan Weispfenning - Vice President and Head of Investor Relations Geoff Martha - Chairman and Chief Executive Officer Gary Corona - Interim Chief Financial Officer Brad Welnick - Vice President, Investor Relations Sean Salmon - Executive Vice President and President, Cardiovascular Portfolio Mike Marinaro - Executive Vice President and President, Medical Surgical Portfolio and Americas Conference Call Participants Patrick Wood - Morgan Stanley Larry Biegelsen - Wells Fargo Robbie Marcus - JP Morgan Vijay Kumar - Evercore ISI Travis Steed - Bank of America Matt Miksic - Barclays Josh Jennings - TD Cowen David Rescott - Baird Shagun Singh - RBC Capital Markets Pito Chickering - Deutsche Bank Ryan Weispfenning Good morning. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations, and I appreciate that you're joining us for our Fiscal ‘25 Third Quarter Video Earnings Webcast. |
seekingalpha.com |
2025-02-18 13:49:08 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Medtronic (MDT) Q3 Earnings |
The headline numbers for Medtronic (MDT) give insight into how the company performed in the quarter ended January 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-18 12:31:29 |
Czytaj oryginał (ang.) |
| Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles |
MDT delivers strong earnings in the fiscal 2025 third quarter, with significant improvements in both gross and operating margins. |
zacks.com |
2025-02-18 12:20:43 |
Czytaj oryginał (ang.) |
| Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast |
Tuesday, Medtronic Plc MDT reported third-quarter 2025 sales of $8.29 billion, missing the consensus of $8.32 billion. |
benzinga.com |
2025-02-18 11:30:15 |
Czytaj oryginał (ang.) |
| Medtronic (MDT) Tops Q3 Earnings Estimates |
Medtronic (MDT) came out with quarterly earnings of $1.39 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.30 per share a year ago. |
zacks.com |
2025-02-18 10:56:10 |
Czytaj oryginał (ang.) |
| Medtronic credits heart-surgery-device growth as profit tops analyst estimates |
Medtronic said it is “starting to see the results” of its investment in new products. |
marketwatch.com |
2025-02-18 09:19:00 |
Czytaj oryginał (ang.) |
| Medtronic beats quarterly profit estimates on strong heart, diabetes device sales |
Medtronic beat Wall Street estimates for quarterly profit on Tuesday, on strong demand for its heart and diabetes devices. |
reuters.com |
2025-02-18 09:14:29 |
Czytaj oryginał (ang.) |
| Medtronic reports third quarter fiscal 2025 financial results |
Delivering durable revenue growth with strong earnings power; strength in Pulsed Field Ablation, Pacing, Structural Heart, Diabetes, and Neuromodulation GALWAY, Ireland , Feb. 18, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key Highlights Revenue of $8.3 billion increased 2.5% as reported and 4.1% organic GAAP diluted EPS of $1.01 increased 2%; non-GAAP diluted EPS of $1.39 increased 7% Company reiterates full year revenue and EPS guidance Cardiac Ablation Solutions revenue increased low-20s on strength of pulsed field ablation (PFA) products U.S. Centers for Medicare and Medicaid (CMS) announced coverage for Renal Denervation for the treatment of Hypertension expected to become final on or before October 11, 2025 Financial Results Medtronic reported Q3 worldwide revenue of $8.292 billion, an increase of 2.5% as reported and 4.1% on an organic basis. |
prnewswire.com |
2025-02-18 08:45:00 |
Czytaj oryginał (ang.) |
| Medtronic: Several Reasons For Optimism Before The Upcoming Earnings Release |
Medtronic: Several Reasons For Optimism Before The Upcoming Earnings Release |
seekingalpha.com |
2025-02-14 21:57:41 |
Czytaj oryginał (ang.) |
| Medtronic (MDT) Increases Yet Falls Behind Market: What Investors Need to Know |
In the closing of the recent trading day, Medtronic (MDT) stood at $92.20, denoting a +0.93% change from the preceding trading day. |
zacks.com |
2025-02-13 20:51:34 |
Czytaj oryginał (ang.) |
| 3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade |
If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constant concern for most families. |
fool.com |
2025-01-04 07:19:00 |
Czytaj oryginał (ang.) |
| Here's Why Medtronic (MDT) Gained But Lagged the Market Today |
Medtronic (MDT) closed at $80.95 in the latest trading session, marking a +0.91% move from the prior day. |
zacks.com |
2025-01-03 21:11:59 |
Czytaj oryginał (ang.) |
| Reasons to Retain Medtronic Stock in Your Portfolio Now |
Investors continue to be optimistic about MDT due to its impressive Neuroscience portfolio. Yet, the dull macroeconomic scenario poses a concern to the company's margins. |
zacks.com |
2025-01-03 10:25:20 |
Czytaj oryginał (ang.) |
| 3 Stocks Helping Bring AI to Healthcare |
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. |
marketbeat.com |
2024-12-31 11:43:04 |
Czytaj oryginał (ang.) |
| My Best Dividend Aristocrats For January 2025 |
The ProShares S&P 500 Dividend Aristocrat ETF rocked a cool 4.85% gain in November, but it's giving up nearly half of its return this year in December. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 41 months of tracking these strategies, two strategies are generating a CAGR superior to NOBL. |
seekingalpha.com |
2024-12-31 08:47:18 |
Czytaj oryginał (ang.) |
| 5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More |
Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care. |
zacks.com |
2024-12-30 10:31:10 |
Czytaj oryginał (ang.) |
| 3 Dividend Stocks to Double Up on Right Now |
It's no secret that inflation has caused prices of goods and services to rise in the last few years. The need to spend more just to maintain your current standard of living is a constant worry for many families. |
fool.com |
2024-12-28 10:30:00 |
Czytaj oryginał (ang.) |
| Medtronic Stock Is Still A Great "Buy" |
Medtronic remains a "Buy" due to its undervalued stock, recent product launches, and resolved supply chain issues, despite underperformance over the past 7 months. The company posted solid Q2 results with revenue up 5.25% YoY and expects organic revenue growth of 4.75%-5% for fiscal 2025. Medtronic's strategic acquisitions and focus on innovation and efficiency are expected to drive sustainable growth and improve margins over the next 1-3 years. |
seekingalpha.com |
2024-12-26 04:36:23 |
Czytaj oryginał (ang.) |
| 4 Dividend Stocks to Double Up on Right Now |
You can pat yourself on the back if you're thinking of loading up your portfolio with dividend-paying stocks -- because they're surprisingly strong wealth builders. (If you weren't thinking of doing so, you can start now! |
fool.com |
2024-12-25 12:15:00 |
Czytaj oryginał (ang.) |
| Medtronic Stock Declines 5.6% in a Month: Time to Buy the Dip? |
MDT stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions. |
zacks.com |
2024-12-20 13:46:08 |
Czytaj oryginał (ang.) |
| 2 Robotic Surgery Stocks Challenging Intuitive Surgical's Lead |
Robotic surgery used to be fodder for science fiction movies. Not anymore. |
marketbeat.com |
2024-12-12 09:01:28 |
Czytaj oryginał (ang.) |
| Buy 1 December Aristocrat Of 67 From 38 With 'Safer' Dividends |
"Dividend Aristocrats |
seekingalpha.com |
2024-12-10 17:42:55 |
Czytaj oryginał (ang.) |
| 2 Healthcare Dividend Stocks to Hold for the Long Haul |
Investors looking for stocks to hold on to for a while might want to consider dividend-paying companies. Besides offering a regular stream of passive income, dividend stocks have generally outperformed their non-dividend peers over the long run. |
fool.com |
2024-12-07 11:17:00 |
Czytaj oryginał (ang.) |
| Medtronic announces cash dividend for third quarter of fiscal year 2025 |
GALWAY, Ireland , Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. |
prnewswire.com |
2024-12-05 18:30:00 |
Czytaj oryginał (ang.) |
| 5 Dividend Aristocrats to Buy Now and Hold Through 2025 |
Dividend Aristocrats are an attractive group of stocks for dividend growth investors because of their blue chip quality and proven track record. The stocks pay reliable dividends and grow their distributions annually, helping to compound returns and offset inflation. |
marketbeat.com |
2024-12-03 09:45:06 |
Czytaj oryginał (ang.) |
| Medtronic: Guidance Raised, Solid Dividend, Shares Still A Bargain |
Medtronic remains a buy due to its attractive valuation and steady EPS growth, despite recent sector-wide selling pressure and modest losses. Q2 results beat Wall Street expectations, with revenue up 5% year-over-year, and management raised FY 2025 revenue and earnings estimates. Key risks include supply chain issues, competition, policy changes, and currency fluctuations, but MDT's free cash flow yield and technical support levels are strong. |
seekingalpha.com |
2024-12-02 14:02:00 |
Czytaj oryginał (ang.) |
| Best Long-Term Investment Stocks to Buy |
Some of the best long-term investment stocks include companies that are in good financial standing, have a low valuation and pay consistent dividends. |
kiplinger.com |
2024-11-29 17:47:35 |
Czytaj oryginał (ang.) |
| Reasons to Retain Medtronic Stock in Your Portfolio Now |
Investors continue to be optimistic about MDT due to its impressive international expansion. Yet, the dull macroeconomic scenario poses a concern to the company's margins. |
zacks.com |
2024-11-29 10:41:21 |
Czytaj oryginał (ang.) |
| MDT Stock May Gain Following the Positive Data From Optimize PRO Study |
Medtronic announces new positive data for its Evolut TAVR from the Optimize PRO clinical research. |
zacks.com |
2024-11-28 14:01:10 |
Czytaj oryginał (ang.) |
| Should You Pick Medtronic Stock At $85? |
Medtronic (NYSE: MDT) reported its Q2 fiscal 2025 results (fiscal ends in April) last week, with revenues and earnings exceeding the street estimates. The company reported revenue of $8.4 billion and adjusted earnings of $1.26 per share, compared to the consensus estimates of $8.3 billion and $1.25, respectively. |
forbes.com |
2024-11-27 08:00:07 |
Czytaj oryginał (ang.) |